Provocatus has announced a significant change to its executive team, with Luke Gartner named as its new managing director.
Writing on LinkedIn, the veteran-owned firm said it was “thrilled” to announce the promotion of Gartner from the position of commercial manager.
“Luke’s appointment gives CEO Kasey Mumford more time to focus on the overall direction of the business for its continued success,” the company wrote.
Gartner’s Linkedin profile showed he previously worked at MediPharm Labs and OneLife Labs before joining Provocatus this year.
Nurotech International
The US Food and Drug Administration (FDA) has granted rare pediatric disease designation (RPDD) for Nurotech International’s lead drug candidate, NTI164, for the treatment of Rett syndrome.
NTI164 is an anti-inflammatory and neuroprotective compound derived from a proprietary cannabis sativa strain which is currently being evaluated in multiple clinical programs targeting neurodevelopmental disorders.
The RPDD program recognises promising therapies being developed for conditions that affect fewer than 200,000 people in the United States. NTI164 was previously granted orphan drug designation by the FDA.
Designation helps facilitate the development of innovative treatments by providing regulatory support, including enhanced FDA guidance during the drug-development process and potential priority review.
When paired with orphan drug designation, sponsors may also benefit from financial incentives such as tax credits for clinical testing, exemption from certain FDA fees, and seven years of US market exclusivity if the therapy is approved.